24812-93-9

Upstream product

• 51885-79-1 4-ethyl-3-nitro-benzoic acid methyl ester 
• 51885-81-5 methyl 4-acetyl-3-nitrobenzoate 
• 4748-80-5 4-ethyl-3-nitro-benzaldehyde 
• 103440-95-5 4-Ethyl-3-nitrobenzoic acid 
• 619-64-7 p-ethylbenzoic acid 

Downstream Products

• 88072-07-5 3-(3-Bromo-propionylamino)-4-ethyl-benzoic acid methyl ester 
• 201286-95-5 6-(methoxycarbonyl)-3-methyl-1H-indazole 
• 1449668-98-7 C₁₇H₁₈N₄O₂ 
• 1429617-95-7 methyl 4-ethyl-3-ethynylbenzoate 
• 1429617-93-5 methyl 4-ethyl-3-((trimethylsilyl)ethynyl)benzoate 
• 868211-93-2 methyl 4-ethyl-3-fluorobenzoate 
• 1427395-09-2 (3-chloro-4-ethylphenyl)methanol 
• 1081551-72-5 methyl 3-chloro-4-ethylbenzoate 
• 1408000-65-6 C₁₀H₁₁N₃O₂ 
• 1290090-05-9 C₁₃H₁₆N₂O₃S 
• 1290090-14-0 4-ethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 51885-92-8 4-Ethyl-3-d-benzoic acid 
• 103441-03-8 3-iodo-4-ethyl-benzoic acid 
• 51885-91-7 methyl 4-ethyl-3-iodobenzoate 

Relevant academic research and scientific papers

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention comprises peptidomimetic compounds which comprise a suitably aniline and aminoalkylbenzene moieties. The instant compounds inhibit the farnesyl-protein transferase enzyme and the farnesylation of certain proteins. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Substituted N-arylazetidinones, β-lactamases potential inhibitors

Two classes of substituted N-aryl azetidinones have been prepared by cyclization of various β-bromopropionanilides. The 7a class possess a carboxylic function in ortho, meta or para of the nitrogen and possibly another alkyl substituent on the aromatic nucleus. In the 7a class, the aromatic nucleus is substituted by a bromomethyl group instead of the alkyl one. Few of these azetidinones show a good affinity for various cell-free β-lactamases preparations, and thus are pretty good competitive inhibitors. Nevertheless, they do not act synergistically with ampicillin on β-lactamase producing bacterial strains. A poor antibacterial activity has been detected for few compounds. The azetidinones 7b which possess a latent electrophilic quinonimine methide function, do not give any progressive (suicide type) inhibition, or inactivation, of the enzymatic activity.